JP: I believe the MedGenesis Study results will be out in a reasonable timeframe or within a month or two. JN said this reality could affect AMBS (if positive).
MedGenesis Therapeutix raises $5.0 million in equity financing to support the Phase II development of GDNF in Parkinson's Disease
Victoria, British Columbia, January 10, 2012 - MedGenesis Therapeutix Inc, a privately held biotechnology company focused on the development of definitive treatments for neurologic disease, announced today that it has raised $5.0 million to support the phase II clinical development of glial cell derived neurotrophic factor protein (GDNF) in Parkinson's disease. GDNF is a naturally-occurring growth factor capable of protecting and promoting the survival of dopamine producing nerve cells.
News 
Market Data 
Discover 
